ETF Holdings Breakdown of XNCR

XNCR institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-30	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	48,752	USD 571,861
2025-09-30	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	5,824	USD 68,316
2025-09-30	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	40,695	USD 477,352
2025-09-30	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	40,695 0.6%	USD 477,352 2.1%
2025-09-30	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	234	USD 2,745
Total =		136,200	USD 1,597,626

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with XNCR

Barclays Initiates Coverage on Xencor (NASDAQ:XNCR)

Research analysts at Barclays began coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set an “underweight” rating and a $6.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential downside of 40.18% from the stock’s previous close. A number […] - 2025-09-19 02:46:44

Xencor (NASDAQ:XNCR) Shares Gap Down After Analyst Downgrade

Xencor, Inc. (NASDAQ:XNCR – Get Free Report)’s share price gapped down prior to trading on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The stock had previously closed at $8.55, but opened at $8.00. Bank of America now has a $12.00 price target on the stock, down […] - 2025-09-05 02:15:52

Xencor (NASDAQ:XNCR) vs. Enliven Therapeutics (NASDAQ:ELVN) Critical Comparison

Xencor (NASDAQ:XNCR – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk. Earnings & Valuation This table compares Xencor and […] - 2025-08-27 04:54:48

Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target […] - 2025-08-22 02:42:55

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. lowered its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 9.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,459 shares of the biopharmaceutical company’s stock after selling 5,126 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:25:57

Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by New York State Teachers Retirement System

New York State Teachers Retirement System boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,326 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during […] - 2025-07-11 05:14:58

Xencor (NASDAQ:XNCR) Trading Down 5.7% Following Insider Selling

Xencor, Inc. (NASDAQ:XNCR – Get Free Report) shares fell 5.7% during trading on Tuesday following insider selling activity. The stock traded as low as $8.67 and last traded at $8.53. 67,899 shares were traded during mid-day trading, a decline of 90% from the average session volume of 664,926 shares. The stock had previously closed at […] - 2025-06-19 02:13:09

Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Average Target Price from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy […] - 2025-06-11 04:40:45

California State Teachers Retirement System Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)

California State Teachers Retirement System increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,130 shares of the biopharmaceutical company’s stock after buying an additional 6,376 shares during the period. […] - 2025-06-10 04:22:46

53,397 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 53,397 shares of the biopharmaceutical company’s stock, valued at approximately $1,227,000. Other large investors have also modified their holdings of the company. Sterling Capital Management LLC boosted […] - 2025-06-03 05:30:52

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 23.4% in the 4th quarter, HoldingsChannel reports. The fund owned 40,355 shares of the biopharmaceutical company’s stock after purchasing an additional 7,650 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Xencor were […] - 2025-05-27 04:46:48

Head to Head Analysis: Xencor (NASDAQ:XNCR) versus Dermata Therapeutics (NASDAQ:DRMA)

Xencor (NASDAQ:XNCR – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations. Valuation and Earnings This table compares Xencor and […] - 2025-05-21 03:14:50

Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […] - 2025-05-13 02:04:46

Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 132.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,865 shares of the biopharmaceutical company’s stock after purchasing an additional 4,482 shares during the quarter. Tower Research […] - 2025-05-06 05:17:02

Dimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)

Dimensional Fund Advisors LP grew its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,501,532 shares of the biopharmaceutical company’s stock after purchasing an additional 102,297 shares during the period. Dimensional Fund […] - 2025-05-05 05:21:10

10,408 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Bank of Montreal Can

Bank of Montreal Can purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $239,000. Several other institutional investors have also added to or reduced their stakes in XNCR. Finepoint Capital LP […] - 2025-04-25 04:36:48

William Blair Begins Coverage on Xencor (NASDAQ:XNCR)

Research analysts at William Blair initiated coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. Wells Fargo & Company dropped their […] - 2025-04-23 02:11:01

Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by Legal & General Group Plc

Legal & General Group Plc lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,514 shares of the biopharmaceutical company’s stock after acquiring an additional 20,141 shares during the quarter. […] - 2025-04-22 04:47:07

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 216,291 shares of the biopharmaceutical company’s stock after selling 16,734 shares during the quarter. Russell Investments […] - 2025-04-15 05:33:08

Pictet Asset Management Holding SA Invests $247,000 in Xencor, Inc. (NASDAQ:XNCR)

Pictet Asset Management Holding SA acquired a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 10,740 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes […] - 2025-04-11 05:58:59

Norges Bank Makes New Investment in Xencor, Inc. (NASDAQ:XNCR)

Norges Bank acquired a new stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 147,823 shares of the biopharmaceutical company’s stock, valued at approximately $3,397,000. A number of other institutional investors and hedge funds have also recently […] - 2025-04-11 05:12:49

Xencor, Inc. (NASDAQ:XNCR) Stock Position Lifted by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,017,366 shares of the biopharmaceutical company’s stock after acquiring an additional 418,040 shares during the period. Vanguard Group Inc. owned 0.11% of Xencor worth $184,239,000 as of its […] - 2025-04-07 05:06:58

Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,715 shares of the biopharmaceutical company’s stock after acquiring an additional 6,810 shares during […] - 2025-04-06 05:30:53

Teacher Retirement System of Texas Buys 3,250 Shares of Xencor, Inc. (NASDAQ:XNCR)

Teacher Retirement System of Texas boosted its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,645 shares of the biopharmaceutical company’s stock after purchasing an additional 3,250 shares during […] - 2025-04-01 04:40:45

Thrivent Financial for Lutherans Has $2.82 Million Stock Position in Xencor, Inc. (NASDAQ:XNCR)

Thrivent Financial for Lutherans grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,897 shares of the biopharmaceutical company’s stock after buying an additional 6,528 shares during the quarter. Thrivent Financial […] - 2025-03-28 06:18:47

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-03-25 04:26:50

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by US Bancorp DE

US Bancorp DE cut its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 75.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,532 shares of the biopharmaceutical company’s stock after selling 7,843 shares during the period. US Bancorp DE’s holdings in Xencor were […] - 2025-03-19 05:10:48

Wells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00

Xencor (NASDAQ:XNCR – Free Report) had its target price lowered by Wells Fargo & Company from $37.00 to $33.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. […] - 2025-03-03 04:21:01

Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-02-28 06:35:19

Xencor, Inc. (NASDAQ:XNCR) Receives $34.88 Consensus PT from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 […] - 2025-02-06 05:14:54

Back to Listing

Disclaimer